慢性乙型肝炎抗病毒治疗若干热点

倪勤; 刘克洲

慢性乙型肝炎抗病毒治疗若干热点

倪勤,
刘克洲

浙江大学医学院附属第一医院传染病诊治国家重点实验室

详细信息

中图分类号: R512.62
计量
- 文章访问数: 2871
- HTML全文浏览量: 9
- PDF下载量: 948
- 被引次数: 0
出版历程
- 出版日期: 2012-03-20

Current issues of antiviral therapy for chronic hepatitis B

Ni Qin,
Liu KeZhou

摘要

摘要: <正>我国新版《指南》(2010版)慢性乙型肝炎(CHB)治疗的总体目标:"最大限度地长期抑制HBV,减轻肝细胞炎症坏死及肝纤维化,延缓或减少肝脏失代偿、肝硬化、肝细胞癌及其并发症的发生,从而改善生活质量和延长存活的时间。"删去了2005年版现阶段难以实现的"清除HBV","阻止疾病进展"的目标,体
- 肝炎,乙型,慢性 /
- 抗病毒药 /
- 干扰素类
- hepatitis B /
- chronic /
- antiviral agents

HTML全文

参考文献(18)

[1] 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010年版) [J].中华临床感染病杂志, 2011, 4 (1) :1-13.

[2]Lau GK, Piratvisuth T, Luo KX, et al.Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronichepatitis B[J].N Engl J Med, 2005, 352 (26) :2682-2695.

[3]Lau GK, Piratvisuth T, Luo KX, et al.Durability of responseand occurrence of late response to peginterferon alfa-2a (40KD) [PEGASYS]one year post-treatment in patientswith HBeAg-positive chronic hepatitis B.EASL 2006.

[4]Liaw YF Xie Q, Han KH, et al.Shorter duration and lower doseof peginterferon alfa-2a therapy results in inferior HBeAg sero-conversion rates compared with the duration and dose of 48weeks and 180μg:NEPTUNE study.Oral Presentation 215.61st AASLD.2010.

[5]Buster EH, Hansen BE, Lau GK, et al.Factors that predictresponse of patients with hepatitis B e antigen-positivechronic hepatitis B to peginterferon-alfa[J].Gastroenterol-ogy, 2009, 137 (6) :2002-2009.

[6]Marcellin P, Piratvisuth T, Brunetto M, et al.Increasingrates of clearance and seroconversion in patients withHBeAg-negative disease treated with Peginterferon Alfa-2a Lamivudine:results of 5-year post-treatment followup.EASL 2009, S336 (924) .

[7]Lampertico P, Vigano M, Dicostanzo G, et al.Extended (2years) treatment with peginterferon alfa-2a (40KD) im-proves sustained response rates in genotype D patients withHBeAg negative chronic hepatitis B.Oral Presentation.45thEASL.2010.

[8]Piratvisuth T, Lau GK, Marcellin P, et al.On-treatment de-cline in serum HBsAg levels predicts sustained immune con-trol and HBsAg clearance 6 months post-treatment inHBeag-positive hepatitis B virus-infected patients treatedwith peginterferon alfa-2a[40 kD] (PEGASYS) .Hepatol Int (2010) 4:94-345.PP211.APASL 2010.

[9]Hoofnagle JH.Therapy of hepatitis B:unresolved issues andremaining challenges.61st AASLD Postgraduate course, 52-55, 2010.

[10]Mao Y, Zeng M, Yao G, et al.Efficacy and safety of 4 yearsadefovir dipivoxil 10 mg (ADV) in Chinese HbeAg+ve chro-nic hepatitis B (CHB) [J].Hepatol Int, 2008, 2 (1) :A98 (PP009) .

[11]Lok AS, McMahon BJ.Chronic hepatitis B:update 2009[J].Hepatology, 2009, 50 (3) :661-662.

[12]European Association for the study of the liver.EASL clinicalpractice guidelines:management of chrotitis B[J].J Hepa-tol, 2009, 50 (2) :227-242.

[13]Marcellin P, Buti M, Kraster Z, et al.Continued efficacy andsafety through 4 years of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-negative patients with chronic hepatitisB (Study 102) :prelimminary analysis.Poster#476.61stAASLD 2010.

[14]Heathcote EJ, Gane EJ, deMan RA, et al.Long term (4year) efficacy and safety of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-positive patients (HBeAg+) with chronic hepatitis B (Study 103) :prelimminary analysis.Poster#477.61st AASLD 2010.

[15]Han Steven-Huy B.Current therapy of hepatitis B.61stAASLD Postgraduate course, 36-43, 2010.

[16]Keeffe EB, Zeuzem S, Koff RS, et al.Report of an interna-tional workshop:Roadmap for management of patients re-ceiving oral therapy for chronic hepatitis B[J].Clin Gastroen-terol Hepatol, 2007, 5 (8) :890-897.

[17]Liaw YF.Meet-the-Professor Luncheon, HBV Therapy:Practice vs.Practice Guidelines.61st AASLD 2010.

[18] 核苷 (酸) 类药物联合治疗慢性乙型肝炎专家建议[J].中华临床感染病杂志, 2011, 4 (2) :65-68.

施引文献

资源附件(0)

访问统计